What We Do
Best-in-Class Antibodies (BICABs) Platform
Design BICABs
- Redesigned, high-value mABs with state-of-the-art knowledge and technology
- Differentiated by better functional ability / reduced toxicity (safer for more patients)
- Optimized for high-yield manufacturability (low COGs)
- Target antibodies in this area include products for oncology/inflammation indications with HIGH market potential
Leverage strategic cell development and manufacturing partnerships
- GMP cell banking
- GMP small to mid-scale manufacturing (bioreactors/purification)
A robust and scalable biotherapeutic production engine
Future Plans
- Set up PraNa lab capable of generating material for analytical testing up to toxicology studies
- Generate proof of best-in-class capabilities using our proprietary platform to generate BiCABs